Dr Reddys Laboratories (RDY) Equity Income (2011 - 2026)

Dr Reddys Laboratories has reported Equity Income for 16 years, with the latest figure at -$84502.1 in Q2 2026.

• On a quarterly basis, Equity Income fell 261.59% year-over-year to -$84502.1 in Q2 2026; TTM through Jun 2026 was $1.4 million, a 23.85% decrease from a year earlier, with the FY2026 full-year figure at -$1.0 million, up 66.67% from the prior year.
• Equity Income was -$84502.1 for Q2 2026 at Dr Reddys Laboratories, down from $503201.4 in the prior quarter.
• The five-year high for Equity Income was $728303.9 in Q3 2024, with the low at -$2.0 million in Q2 2023.
• Average Equity Income over 5 years is -$212897.1, with a median of $117454.2 recorded in 2025.
• The sharpest annual moves came in 2023 and 2026: Equity Income soared 150.81% in 2023, then plunged 261.59% in 2026.
• Over 5 years, Equity Income stood at -$1.0 million in 2022, then surged by 132.43% to $324267.2 in 2023, then jumped by 53.4% to $497435.0 in 2024, then sank by 48.08% to $258277.9 in 2025, then tumbled by 132.72% to -$84502.1 in 2026.
• The last three Equity Income figures came in at -$84502.1 (Q2 2026), $503201.4 (Q1 2026), and $258277.9 (Q4 2025), per Business Quant data.